Market Place
Sourcing Support
Polivy Combo Therapy Confirmed as Standard in Aggressive Lymphoma
09 Dec 2024 //
BUSINESSWIRE
Poxel, OrbiMed Agreement To Monetize TWYMEEG® Royalties, $50M
30 Sep 2024 //
BUSINESSWIRE
Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update
09 Sep 2024 //
BUSINESSWIRE
Sumitomo And Poxel Announce TWYMEEG® Post-Marketing Study Results In Japan
07 Aug 2024 //
BUSINESSWIRE
Poxel Updates Q2 Financials Reschedules Annual General Meeting
15 Jul 2024 //
BUSINESSWIRE
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
16 May 2024 //
BUSINESSWIRE
Poxel Q1 2024 Financial Update, Delays 2023 Full Year Release
29 Apr 2024 //
BUSINESSWIRE
Poxel to Report Its 2023 Annual Results by the End of April 2024
28 Mar 2024 //
BUSINESSWIRE
Poxel Reports Cash and Revenue for the Full Year 2023
15 Feb 2024 //
BUSINESSWIRE
Poxel Provides Corporate Update
21 Dec 2023 //
BUSINESSWIRE
Poxel Reports Cash and Revenue for the Third Quarter
08 Nov 2023 //
BUSINESSWIRE
Poxel Announces its Participation at Upcoming Investor Conferences
12 Oct 2023 //
BUSINESSWIRE
Poxel Announces its Participation at Upcoming Scientific Conference
02 Oct 2023 //
BUSINESSWIRE
Poxel takes writedown on NASH drug as it continues layoffs, search for cash
27 Sep 2023 //
ENDPTS
Poxel to Report 2023 First Half-Year Results
06 Sep 2023 //
BUSINESSWIRE
Poxel Reports Cash and Revenue for the 2Q & 1ST Half 2023 & Provides Update
30 Aug 2023 //
BUSINESSWIRE
Poxel Announces Participation at H.C. Wainwright 2nd Annual Kidney Conference
18 Jul 2023 //
BUSINESSWIRE
Poxel, winner of the 2023 edition of the I-nov contest
05 Jul 2023 //
BUSINESSWIRE
Poxel Announces its Participation at Patient Association Conferences
15 Jun 2023 //
BUSINESSWIRE
Poxel Reports Cash and Revenue for the First Quarter 2023
17 May 2023 //
BUSINESSWIRE
Poxel Announces Notice of Its Annual Meeting to Be Held on June 21, 2023
16 May 2023 //
BUSINESSWIRE
Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales
15 May 2023 //
BUSINESSWIRE
Poxel Announces Upcoming Participation at the JMP Securities Life Science
10 May 2023 //
BUSINESSWIRE
Poxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted
20 Apr 2023 //
BUSINESSWIRE
Poxel Announces Cash Runway Extended Through Q2 2025
23 Mar 2023 //
BUSINESSWIRE
Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update
23 Mar 2023 //
BUSINESSWIRE
Poxel to Report its 2022 Full Year Results by the End of March 2023
22 Mar 2023 //
BUSINESSWIRE
Poxel will Report its 2022 Full Year Results on March 23, 2023
22 Mar 2023 //
BUSINESSWIRE
Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event
15 Mar 2023 //
BUSINESSWIRE
Poxel Announces Publication of Positive PII Results from NASH Trial for PXL065
08 Mar 2023 //
BUSINESSWIRE
Poxel Announces Publication in Kidney International of PXL770 Results in ADPKD
01 Mar 2023 //
BUSINESSWIRE
Poxel Reports Cash and Revenue for Full Year 2022 and Provides Corporate Update
15 Feb 2023 //
BUSINESSWIRE
Poxel Receives Orphan Drug Designation from EC for PXL770 and PXL065
25 Jan 2023 //
BUSINESSWIRE
Poxel Announces Upcoming Participation at Investor Conferences
04 Jan 2023 //
BUSINESSWIRE
Poxel Announces Drawdown of the Remaining Two Tranches
22 Dec 2022 //
BUSINESSWIRE
Poxel ProvidesUpdate and Reports Cash and Revenue for the 3Q & Nine Months 2022
08 Nov 2022 //
BUSINESSWIRE
Poxel Announces Participation at the Jefferies London Healthcare Conference
07 Nov 2022 //
BUSINESSWIRE
Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH
07 Nov 2022 //
BUSINESSWIRE
Poxel Announces Presentation at the H.C. Wainwright Annual NASH Conference
13 Oct 2022 //
BUSINESSWIRE
Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD
12 Oct 2022 //
BUSINESSWIRE
Availability of Poxel`s 2022 Half-Year Financial Report
04 Oct 2022 //
BUSINESSWIRE
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA
03 Oct 2022 //
BUSINESSWIRE
Poxel reports positive histology results from DESTINY-1 phase 2 trial of PXL065
22 Sep 2022 //
PHARMABIZ
Poxel Announces Results from PII NASH Trial for PXL065
21 Sep 2022 //
BUSINESSWIRE
Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update
21 Sep 2022 //
BUSINESSWIRE
Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065
29 Aug 2022 //
BUSINESSWIRE
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement
08 Aug 2022 //
BUSINESSWIRE
Poxel Provides Corporate Update and Reports Second Quarter and First Half 2022
08 Aug 2022 //
BUSINESSWIRE
Poxel to Publish Two PC Articles on X-Linked Adrenoleukodystrophy
05 Jul 2022 //
BUSINESSWIRE
Poxel Announces Results from June 21, 2022 Annual and General Meeting
22 Jun 2022 //
BUSINESSWIRE
Poxel Announces New Solid Form Patent for PXL065
08 Jun 2022 //
BUSINESSWIRE
Poxel Announces its Participation in Upcoming Investor & Scientific Conferences
31 May 2022 //
BUSINESSWIRE
Poxel`s PXL065 & PXL770 Granted ODD from FDA for X-Linked Adrenoleukodystrophy
17 May 2022 //
BUSINESSWIRE
Poxel Reports Cash and Revenue for the First Quarter 2022
17 May 2022 //
BUSINESSWIRE
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022
13 May 2022 //
BUSINESSWIRE
Poxel Announces Availability of Its 2021 Universal Registration Document
04 May 2022 //
BUSINESSWIRE
Poxel Announces PXL770 Awarded FDA FTD for X-linked Adrenoleukodystrophy
11 Apr 2022 //
BUSINESSWIRE
Poxel to Report Financial Results for FY 2021 and Host Webcast Call
15 Mar 2022 //
BUSINESSWIRE
Poxel Announces PXL065 Granted FDA FTD for X-linked Adrenoleukodystrophy
16 Feb 2022 //
BUSINESSWIRE
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021
16 Feb 2022 //
BUSINESSWIRE
